Details

Principles of Biomedical Sciences and Industry


Principles of Biomedical Sciences and Industry

Translating Ideas into Treatments
1. Aufl.

von: Markus Hinder, Alexander Schuhmacher, Jörg Goldhahn, Dominik Hartl

97,99 €

Verlag: Wiley-VCH
Format: EPUB
Veröffentl.: 22.07.2022
ISBN/EAN: 9783527824007
Sprache: englisch
Anzahl Seiten: 448

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

<b>Principles of Biomedical Sciences and Industry</b> <p><b>Improve your product development skills to bring new ideas to biomedicine</b> <p>The development of innovative healthcare products, such as biodegradable implants, biopharmaceuticals, or companion diagnostics, requires a multi-disciplinary approach that incorporates scientific evidence with novel and innovative ideas to create new and improved products and treatments. Indeed, product development and the integration of science with commercial aspects have become key challenges for scientists working in the pharmaceutical, biotech, and medtech industries. <p>Using a multi-pronged approach to development, <i>Principles of Biomedical Sciences and Industry</i> combines ideas and methodologies from four of the central areas of focus in the biomedical arena: pharmaceuticals, diagnostics, biomaterials, and medical devices. In doing so, the book covers the entire product lifecycle, from translating a scientific idea into a prototype to product development, launch, and management. <p><i>Principles of Biomedical Sciences and Industry </i>readers will also find: <ul><li>Several case studies from the most important product categories (pharmaceuticals, diagnostics, medical devices, combination products)</li> <li>Chapters dealing with toxicology and safety risks in development, as well as regulatory approval </li> <li>Key business aspects including how to secure funding, managing intellectual property, and price regulation in the market</li> <li>An ideal resource for teachers and students that conveys the information in an easily-digestible format </li></ul> <p>Ideal for advanced students and young professionals pursuing a career in the biomedical and healthcare industries, <i>Principles of Biomedical Sciences and Industry</i> is an essential reference for those in pharmaceutical industry, biotechnologists, medicinal chemists, bio-engineers, pharma engineers, and management consultants.
THE BIOMEDICAL INDUSTRY<br> Material science industry<br> Diagnostics industry<br> Medical technology industry<br> Pharmaceutical industry<br> <br> THE LONG WAY TO LAUNCH A NEW PRODUCT<br> The standardized R&D process<br> Drug Discovery: From idea to candidate<br> Drug Development: From prototype to product<br> The Impact of translational science<br> Market launch and product LCM<br> Impact of quality management<br> The regulatory framework<br> Case-in-point: The R&D process in medical devices and technology<br> Case-in-point: The R&D process in (mobile) diagnostics<br> <br> STRATEGIC R&D MANAGEMENT<br> The what and how of the industry<br> Portfolio assessment<br> Portfolio management and decision making<br> Technology Management<br> Project management<br> IP management<br> <br> REAL LIFE IN THE INDUSTRY -<br> APPLICATIONS IN LIFE SCIENCE<br> Studies of success and failure<br> Today's challenges and future trends<br>
<p><b>Markus Hinder</b> studied medicine at the Universities of Heidelberg, Paris and Zürich and obtained a doctoral degree in pharmacology from Heidelberg University. After graduation he trained in clinical pharmacology, cardiology and emergency medicine. He underwent postgraduate training in clinical trial methodology and statistics at the Universities of Basel and Brussels. He joined the pharmaceutical industry more than 20 years ago and held senior leadership positions in translational medicine, clinical development, medical affairs, project management, and drug safety. He has been lecturing pharmacology and pharmaceutical R&D since 2004. In 2010 he was appointed professor at Cardiff University/ Hochschule Fresenius. He serves as a reviewer for several journals and associate editor for the <i>Journal of Translational Medicine</i>.</p> <p><b>Alexander Schuhmacher</b> graduated in biology from the University of Konstanz (Germany), in pharmaceutical medicine at the University of Witten/Herdecke (Germany) and did a Ph.D. in molecular biology at the University of Konstanz; he is also a graduate of the Executive MBA program at the University of St. Gallen (Switzerland). Alexander holds a full professorship in life science management at the Technische Hoch-schule Ingolstadt (Germany). His research focus is on biopharmaceutical innovation management with a specialization on R&D efficiency, artificial intelligence and open innovation. Prior to that, Alexander worked 9 years as professor at Reutlingen University (Germany) and 14 years in various R&D leadership positions in the pharmaceutical industry.</p> <p><b>Jörg Goldhahn</b> received his M.D. in 1997 from the Friedrich-Schiller University in Jena, Germany, finished a postgraduate course (MAS) in Medical Physics and Biomechanics at the ETH Zurich in 2000, received the postdoctoral lecture qualification (Habilitation) in 2008 and became a faculty member of the department for health sciences and technology (D-HEST) as adjunct professor in 2014. He worked as a translational medicine expert at the Novartis Institutes for Biomedical Research (NIBR) in Basel in addition to more than 15 years in clinical research. He is currently the head of the Institute for Translational Medicine and medical director of the bachelor in medicine at ETH Zurich, Switzerland.</p> <p><b>Dominik Hartl</b> studied Medicine at the Universities of Regensburg, Munich and Melbourne and obtained his doctoral degree in Immunology from Munich/LMU University. He is board certified in Pediatrics and Infectious Diseases and worked as Physician Scientist/Post-Doc Scholar at Yale University. He joined the pharmaceutical industry more than 6 years ago and gained extensive experience in his positions in Drug Discovery, Translational Medicine, Biomarkers and Precision Medicine/Personalized Healthcare in Biotech and Big Pharma. In addition to working in the pharmaceutical industry, Dominik is a Professor for Pediatric Immunology/Infectious Diseases at the University of Tübingen.</p>
<p><b>Improve your product development skills to bring new ideas to biomedicine</b></p> <p>The development of innovative healthcare products, such as biodegradable implants, biopharmaceuticals, or companion diagnostics, requires a multi-disciplinary approach that incorporates scientific evidence with novel and innovative ideas to create new and improved products and treatments. Indeed, product development and the integration of science with commercial aspects have become key challenges for scientists working in the pharmaceutical, biotech, and medtech industries. <p>Using a multi-pronged approach to development, <i>Principles of Biomedical Sciences and Industry</i> combines ideas and methodologies from four of the central areas of focus in the biomedical arena: pharmaceuticals, diagnostics, biomaterials, and medical devices. In doing so, the book covers the entire product lifecycle, from translating a scientific idea into a prototype to product development, launch, and management. <p><i>Principles of Biomedical Sciences and Industry </i>readers will also find: <ul><li>Several case studies from the most important product categories (pharmaceuticals, diagnostics, medical devices, combination products)</li> <li>Chapters dealing with toxicology and safety risks in development, as well as regulatory approval </li> <li>Key business aspects including how to secure funding, managing intellectual property, and price regulation in the market</li> <li>An ideal resource for teachers and students that conveys the information in an easily-digestible format </li></ul> <p>Ideal for advanced students and young professionals pursuing a career in the biomedical and healthcare industries, <i>Principles of Biomedical Sciences and Industry</i> is an essential reference for those in pharmaceutical industry, biotechnologists, medicinal chemists, bio-engineers, pharma engineers, and management consultants.
"Life science students and postgraduates in search of an integrated overview of drug development now have a textbook which provides state-of-the-art insights into the science and art of developing new drugs and medical devices."<br> Dr. Gerd A. Kullak-Ublick<br> Chair and Professor of Clinical Pharmacology and Toxicology, University of Zurich and University Hospital Zurich<br> <br> <br> "If sciences is the background of pharma innovation it is at the core however an industrial process. This book helps a lot to understand it very clearly."<br> Dr. Marc Cluzel<br> Chairman of the Supervisory Board of MorphoSys and former Executive Board Member R&D Sanofi<br> <br> <br> "I will recommend this gap filling book to students and to those readers who aim to work in or with biopharmaceutical industry. It perfectly describes all important aspects of the fascinating route from translating ideas to patient treatment."<br> Dr. Heike A. Wieland<br> Professor of Pharmacology, Institute of Pharmacology and Toxicology, Ulm University<br> <br> <br> "A brilliant idea is not yet an innovation. An innovation is only an innovation if it reaches the patient. Therefore, it is mandatory to bring academic and industrial biomedical sciences together as close as possible. This book contributes significantly to this purpose, congratulations!"<br> Prof. Dr. Jochen Maas<br> General Manager Sanofi R&D Germany<br> <br> <br> "Drug Discovery and Development are inter-disciplinary by nature. This book nicely illustrates the complexities, challenges and potentials of academia-industry interactions in that space."<br> Charles de la Cruz, MD, PhD<br> Associate Professor of Medicine, Director, Center for Pulmonary Infection Research and Treatment (CPIRT), Yale University<br> <br> <br> "This textbook will be an invaluable source for students in their studies and assignments. With its unique combination of practical insights and theoretical analysis it is a must-read for any life science student in the field of innovation management in the pharmaceutical industry."<br> Prof. Dr. Rainer Turck<br> Dean of the Faculty Economics & Media, Hochschule Fresenius, University of Applied Sciences<br> <br> <br> "This unique book provides valuable contemporary insights into innovation topics of the pharmaceutical business. Highly recommended for life science students and professionals in academia and industry."<br> Dr Joachim Scholpp, MD, PhD, DESA<br> Global Head Translational Medicine CNS, Retinal Health & Emerging Areas, Boehringer Ingelheim Pharma GmbH & Co. KG<br> <br> <br> "One major challenge in delivering high value medicines has been consistent understanding of precision medicine terminology and biomarker use in clinical studies. This book does a terrific job in educating and providing case study examples to help us all align on this journey." Dr. Scott Kennedy<br> Global Head of Biomarker Development, Novartis Institutes for BioMedical Research<br>

Diese Produkte könnten Sie auch interessieren:

Hot-Melt Extrusion
Hot-Melt Extrusion
von: Dennis Douroumis
PDF ebook
136,99 €
Hot-Melt Extrusion
Hot-Melt Extrusion
von: Dennis Douroumis
EPUB ebook
136,99 €
Kunststoffe
Kunststoffe
von: Wilhelm Keim
PDF ebook
99,99 €